Latest News
-
Monday - December 12, 2016
Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing
BlueRock Therapeutics is focused on breakthrough treatments based on latest stem cell technology in combination with superior cell differentiation protocols / BlueRock Therapeutics’ vision is to cure diseases with significant cell loss and diminished self-repair potential with an initial focus on cardiovascular, neurological and other conditions » more
-
Monday - December 12, 2016
New edition of research, the Bayer scientific magazine, published
Big Data meets Life Sciences
Key topics in medical and plant research: disease genomics, herbicide resistance, big data analysis for new therapies / Experiencing and understanding the fascination of science: all topics also available in the online edition of research with animated graphics, videos and photo galleries » more
-
Wednesday - December 7, 2016
Bayer strengthens U.S. animal health portfolio:
Boehringer Ingelheim Vetmedica, Inc. and Bayer Enter Into Agreement for Purchase of U.S. Cydectin® Product Portfolio » more
-
Monday - December 5, 2016
Bayer and FaunaPhotonics form research collaboration to develop sensor technology for improved monitoring of insect pests » more
-
Monday - November 28, 2016
Not intended for U.S. and UK Media - American Society of Hematology (ASH) Annual Meeting & Exposition 2016:
Ten Abstracts on the Use of Bayer’s Xarelto® in Different Patient Populations Accepted for Presentation at ASH 2016 » more
-
Thursday - November 24, 2016
Bayer supports public access to safety-relevant crop protection study reports » more
-
Thursday - November 17, 2016
Novel Immunostimulant Adds Value to Bovine Respiratory Disease Protocols
New study involving a novel immunostimulant reveals significant reductions in overall feedlot cattle mortality and demonstrates potential in reducing overall antibiotic use » more
-
Wednesday - November 16, 2016
Bayer at EuroTier 2016: » more
-
Wednesday - November 16, 2016
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA
Bayer successfully places EUR 4 billion of mandatory convertible notes » more
-
Tuesday - November 15, 2016
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA
Bayer to issue mandatory convertible notes » more
-
Tuesday - November 15, 2016
CDP publishes new water ranking:
Bayer an international leader in sustainable water management
Board of Management member Dr. Klusik: “Efficient use of resources has been a cornerstone of our sustainability strategy for a number of years” / Institutional investors rely on CDP rating » more
-
Tuesday - November 15, 2016
Neglected Tropical Diseases
Bayer to fight Chagas disease in children
New formulation of Nifurtimox to be developed for weight-adjusted doses in children of all age groups / Phase III study in Argentina, Colombia, and Bolivia » more
-
Monday - November 14, 2016
Not intended for U.S. and UK Media - New Study Presented at American Heart Association (AHA) Scientific Sessions 2016:
Bayer’s Xarelto® Significantly Reduced Bleeding Compared to VKA in AF-Patients also Receiving Antiplatelet Therapy After Percutaneous Coronary Intervention
PIONEER AF-PCI is the first randomised study of a non-vitamin K antagonist oral anticoagulant (NOAC) in this patient population / Data were presented in a late-breaking clinical trial session at AHA and published simultaneously in The New England Journal of Medicine » more
-
Thursday - November 10, 2016
Joint development of innovative crop protection solutions in agriculture:
Bayer becomes partner of the Centre for Crop Health and Protection consortium » more
-
Thursday - November 10, 2016
Not intended for U.S. and UK Media
Bayer comments on article in „Handelsblatt“ regarding the anticoagulant Xarelto®
Health authorities in Europe and the U.S. have confirmed the positive benefit-risk profile of Xarelto / Potential malfunctioning of the monitoring devices did not affect the study results / During the pivotal trial, the monitoring devices were approved for use by the health authorities and CE certified / Management of bleeding is established for the novel anticoagulants as well / Novel anticoagulants represent medical progress and have proven themselves in clinical practice » more
-
Monday - November 7, 2016
Not intended for U.S. and UK Media - American Heart Association (AHA) Scientific Sessions 2016:
PIONEER AF-PCI Study with Bayer’s Xarelto® Accepted as Late-Breaking Clinical Trial Presentation at AHA 2016 » more
-
Monday - November 7, 2016
Not intended for U.S. and UK Media
Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer
Regulatory submissions in the U.S., Japan and Europe were completed based on data from the Phase III RESORCE study, in which regorafenib demonstrated statistically significant improvement in overall survival / Currently there are no approved therapies for the treatment of unresectable hepatocellular carcinoma (HCC) in the second-line setting » more
-
Monday - October 31, 2016
Life sciences partner in a global start-up network
Bayer and CUBE open cooperation space in Berlin » more
-
Wednesday - October 26, 2016
Bayer AG Third Quarter 2016 Results and News Conference Call » more
-
Wednesday - October 26, 2016
Third quarter of 2016:
Bayer shows strong performance – Acquisition of Monsanto agreed
Group sales increase by 2.3 percent (Fx & portfolio adj. 3.5 percent) to EUR 11,262 million / Pharmaceuticals sustains very good business development / Moderate increase in sales at Consumer Health / Crop Science successful in a persistently difficult market environment / EBITDA before special items up by 6.0 percent to EUR 2,682 million / Net income improves by 18.8 percent to EUR 1,187 million / Core earnings per share increase by 2.4 percent to EUR 1.73 / Forecast for core earnings per share raised / Agreed acquisition of Monsanto creates a global leader in agriculture » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Wednesday, September 5, 2018
Interim Report Second Quarter 2018 / Investor Conference Call
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV